BioNexus Gene Lab Corp Common stock (BGLC) - Net Assets
Based on the latest financial reports, BioNexus Gene Lab Corp Common stock (BGLC) has net assets worth $6.82 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.62 Million) and total liabilities ($804.97K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BGLC cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.82 Million |
| % of Total Assets | 89.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | 24.93% |
| 10-Year Change | N/A |
| Growth Volatility | 527.28 |
BioNexus Gene Lab Corp Common stock - Net Assets Trend (2016–2024)
This chart illustrates how BioNexus Gene Lab Corp Common stock's net assets have evolved over time, based on quarterly financial data. Also explore BioNexus Gene Lab Corp Common stock asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for BioNexus Gene Lab Corp Common stock (2016–2024)
The table below shows the annual net assets of BioNexus Gene Lab Corp Common stock from 2016 to 2024. For live valuation and market cap data, see BGLC market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $8.32 Million | -13.82% |
| 2023-12-31 | $9.66 Million | +44.90% |
| 2022-12-31 | $6.67 Million | -7.17% |
| 2021-12-31 | $7.18 Million | +7.77% |
| 2020-12-31 | $6.66 Million | +493.58% |
| 2019-12-31 | $1.12 Million | -26.25% |
| 2018-12-31 | $1.52 Million | +1508.36% |
| 2017-12-31 | $94.63K | +7317.85% |
| 2016-12-31 | $-1.31K | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioNexus Gene Lab Corp Common stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 344118200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $17.33 Million | 208.25% |
| Other Comprehensive Income | $-555.00K | -6.67% |
| Total Equity | $8.32 Million | 100.00% |
BioNexus Gene Lab Corp Common stock Competitors by Market Cap
The table below lists competitors of BioNexus Gene Lab Corp Common stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Crown Confectionery Co Ltd Pref
KO:26490K
|
$4.92 Million |
|
Tarena International Inc
NASDAQ:TCTM
|
$4.92 Million |
|
Lycaon Resources Ltd
AU:LYN
|
$4.92 Million |
|
Soco Corporation Ltd
AU:SOC
|
$4.93 Million |
|
Permaju Industries Bhd
KLSE:7080
|
$4.91 Million |
|
TENET FINTECH GROUP INC.
F:P0T
|
$4.91 Million |
|
2cureX AB
ST:2CUREX
|
$4.90 Million |
|
China Natural Resources Inc
NASDAQ:CHNR
|
$4.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioNexus Gene Lab Corp Common stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,657,852 to 8,322,804, a change of -1,335,048 (-13.8%).
- Net loss of 1,598,342 reduced equity.
- Dividend payments of 68,130 reduced retained earnings.
- Other comprehensive income increased equity by 122,294.
- Other factors increased equity by 209,130.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.60 Million | -19.2% |
| Dividends Paid | $68.13K | -0.82% |
| Other Comprehensive Income | $122.29K | +1.47% |
| Other Changes | $209.13K | +2.51% |
| Total Change | $- | -13.82% |
Book Value vs Market Value Analysis
This analysis compares BioNexus Gene Lab Corp Common stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.45x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.00 | $2.08 | x |
| 2017-12-31 | $0.15 | $2.08 | x |
| 2018-12-31 | $2.75 | $2.08 | x |
| 2019-12-31 | $1.56 | $2.08 | x |
| 2020-12-31 | $7.77 | $2.08 | x |
| 2021-12-31 | $5.03 | $2.08 | x |
| 2022-12-31 | $4.63 | $2.08 | x |
| 2023-12-31 | $5.61 | $2.08 | x |
| 2024-12-31 | $4.67 | $2.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioNexus Gene Lab Corp Common stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16.81%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 1.25x
- Recent ROE (-19.20%) is above the historical average (-19.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-703.90 |
| 2017 | -130.78% | -114.92% | 0.08x | 13.45x | $-133.21K |
| 2018 | 1.74% | 12.46% | 0.13x | 1.09x | $-125.74K |
| 2019 | -21.96% | -194.14% | 0.10x | 1.10x | $-358.71K |
| 2020 | 16.42% | 9.61% | 1.13x | 1.52x | $427.88K |
| 2021 | 10.47% | 5.62% | 1.40x | 1.33x | $33.59K |
| 2022 | -5.34% | -3.26% | 1.25x | 1.31x | $-1.02 Million |
| 2023 | -27.22% | -26.91% | 0.86x | 1.18x | $-3.59 Million |
| 2024 | -19.20% | -16.81% | 0.91x | 1.25x | $-2.43 Million |
Industry Comparison
This section compares BioNexus Gene Lab Corp Common stock's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $2,244,392,490
- Average return on equity (ROE) among peers: 7.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioNexus Gene Lab Corp Common stock (BGLC) | $6.82 Million | 0.00% | 0.12x | $4.91 Million |
| Albemarle Corp (ALB) | $4.09 Billion | 13.03% | 1.41x | $19.80 Billion |
| Alto Ingredients Inc (ALTO) | $225.06 Million | -26.21% | 0.78x | $212.84 Million |
| Aemetis Inc (AMTX) | $-22.20 Million | 0.00% | 0.00x | $154.69 Million |
| Air Products and Chemicals Inc (APD) | $11.18 Billion | 13.40% | 0.72x | $62.29 Billion |
| Ashland Global Holdings Inc (ASH) | $1.44 Billion | 10.05% | 2.77x | $2.37 Billion |
| Avient Corp (AVNT) | $1.71 Billion | 7.69% | 1.85x | $3.16 Billion |
| Axalta Coating Systems Ltd (AXTA) | $1.54 Billion | 17.15% | 3.69x | $5.92 Billion |
| Balchem Corporation (BCPC) | $2.80 Million | 14.29% | 1.07x | $5.17 Billion |
| Bon Natural Life Ltd (BON) | $30.09 Million | 20.73% | 0.24x | $7.91 Million |
About BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; a… Read more